Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Status:
Terminated
Trial end date:
2020-01-15
Target enrollment:
Participant gender:
Summary
The purpose of the ATLAS study is to determine how patients with locally advanced
unresectable or metastatic urothelial carcinoma respond to treatment with rucaparib.